APOB and atherosclerosis: In addition, there is robust evidence that reducing the plasma concentration of LDL-C reduces the risk of ASCVD.1 In line with the causal relation between apoB and ASCVD, it has been shown that the ASCVD risk reduction of lipid-lowering therapies is proportional to the magnitude and duration of the reduction of apoB-containing particles.